We are commercializing the first water soluble plant based skin substitute to accelerate healing with less scarring and intact hair follicles and sweat glands. We are developing a hand held bed side application of sprayable skin for military and wound healing applications.

Providing management consulting services in Biotechnology, Pharmaceutical, Consumer Health and Technology organizations. Projects have been to build, revitalize and optimize organizational infrastructures, products and sales/marketing strategies.Presently helping wound healing company develop compound for commercialization and serving as US business adviser for Australian client.. Expertise in Wound healing, Regenerative Medicine, cosmetics, Aesthetic Dermatology and Oncology.

Eqalix,Inc.is a development stage Regenerative Medicine company using nanotechnology to create first in class therapies in wound healing, Aesthetic Dermatology, cardiovascular repair and neural regenerative therapies. The technologies encompass areas in tissue regeneration, drug and cell delivery, and replacement of small diameter vessels.As Co-Founder, I worked as sole company employee to shape strategy, develop technologies and prepare technologies for commercialization. Established distinguished Board of Scientific Advisers, won two research grants, developed two human clinical trial protocols,and presented at numerous scientific meetings while developing NIH and DOD grant proposals.

OrthoMend Research has established itself as the emerging developer of absorbable Orthopedic bone fixation devices. We have established offices in the City Center Life Sciences incubator to further our commercialization activities.

OrthoMend is an orthopedic start up specializing in bone fixation with a bio-absorbable polymer reinforced with nano-diamonds. We are commercializing absorbable screws that will allow drug delivery,bone growth and in-vivo diagnostic platforms to replace current metal devices. Devices are intended to enhance the lives and outcomes of patients who suffer fractures and post surgical trauma.

TR Therapeutics, Inc. is a Tissue Regenerative Medicine Company, focused on the Regenerative Medicine and Aesthetic Dermatology markets.We are a clinical stage biopharmaceutical company focused on discovering and developing a novel class of drugs intended to accelerate human wound healing and tissue repair in external acute and chronic wounds. The Company’s lead product candidate, TR-987, is initially being developed for applications in regenerative medicine, including diabetic ulcers and venous ulcers, and Aesthetic Medicine, including for use after ablative procedures. TR-987 has not been approved by the U.S. Food and Drug Administration for commercial distribution.

Glycotex, Inc. is an emerging, clinical stage, product development Biotechnology Company. The company is focused on developing a novel class of wound healing therapeutics for the treatment of chronic ulcers and other wound healing indications, including surgical and traumatic wounds undergoing secondary healing The company has completed a clinical phase 2 study (in Australia) and is currently transitioning product development to the United States with the filing of a US Investigational New Drug Application targeted for early 2007. Glycotex’ products are developed to be used in institutional and home based care for serious wounds and common surgical conditions. We are developing an extensive line of products and delivery options and will be used in conjunction with existing treatment protocols and standard medical interventions.

Regenicin is playing a critical role in the development of the therapeutic candidate, PermaDerm™, an exciting breakthrough technology that uses the patient’s own skin cells to generate living, tissue-engineered skin for the treatment of severe burns. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days.Work is a continuation of six years of efforts to commercialize multiple technologies in parallel at McCoy Enterprises. We had a name changed when company taken public. In essence, seven years of continued work appears here to be less than one.

Developed portfolio of four technologies in Biotechnology and pharmaceuticals to include buccal drug delivery platform for inhaled insulin, wound healing topical product, a cultured autologous skin substitute for aesthetic dermatology, burns and wounds and enzymatic therapy for psoriasis.Two technologies were liquidated as out-licensing contracts and PermaDerm skin substitute was taken public as my next company Regenicin.

I oversee all sales efforts in selling patient recruitment services for Clinical trials in pharmaceutical research. My group interacts with pharmaceutical and biotech sponsors, CRO's, SMO's and academia.

A global contract manufacturing, formulations and analytical chemistry service provider to the pharmaceutical industry. Responsible for global sales and business development.

Responsibilities included overseeing acquisition of products from Allergan to include Naftin, Aqua Glycolic and others. Managed two sales forces, one group full time and another contract part time representatives.Launched and managed channel distribution of Mederma scar removal gel.

Responsible for International Sales, Business Development and Marketing. Managed and partnered with cutting edge companies commercializing. Intellectual property in Aerosol, Pulmonary and Nasal Drug Delivery Devices. Presented off balance sheet joint venture for developing nasal drug delivery corporation. Worked with R&D groups globally to develop, manufacture and commercialize drug Delivery Devices.

Developed Regional sales team for novel Oncology Technology and anti-infective products. Managed two product launches. Developed off-label reimbursement strategy for Atlantic Region.Placed multiple oncology clinical trials in solid tumor indications for development of experimental cancer therapies including Doxil and Amphotec. Led my fellow directors in total solid tumor clinical trial placements

Hired, trained and managed sales organization of 155 sales Representatives, 8 Division Sales managers, and staff. Launched successful cardiovascular product line while co-promoting various lines of metabolic and analgesic pharmaceuticals.Corporate liaison with Boehringer Mannheim Diagnostics to launch Troponin-T cardiac enzyme test.

Series of successful positions of increasing responsibility through territory sales, institutional sael, sales training and Sales management. Awarded numerous honors for exceptional performance.Launched products in cardiovascular, dermatology, GI, Infectious diseases and pain management.